Through a public-private partnership between ASPR’s Biomedical Advanced Research and Development Authority (BARDA) and Sanofi Pasteur, HHS announced this week a six-year, $226 million contract to increase capacity to produce recombinant influenza vaccine in the United States. The contract is in accordance with the September 19 presidential executive order to enhance national security and the public health by modernizing influenza vaccines and technologies.

Exercise Templates Now Available to
Help Identify, Assess, Treat, Manage,
and Transport Patients during a
Highly Infectious Disease Outbreak

Webinar Panelists to Discuss Potential
Effects of a Chemical Incident,
Share Lessons Learned in Assessing,
Triaging, and Treating Patients

National Biodefense Science Board
Releases Recommendations to
Standardize National Training and
Readiness for Providers who Deliver
Specialized Care during Disasters

ASPR, CDC, NIH, FDA Testify before
House Committee on Energy and
Commerce about Current Influenza
Season and Ongoing Influenza-related
Research and Innovation

There’s No Such Thing as Just-in-time
Healthcare & Public Health
Preparedness: Strengthening
Partnerships to Enhance Critical
Infrastructure Protection

Giving Your Community Health,
Warmth & Resilience:
MRC Volunteers Strengthen
Communities during the Holiday
Season and Beyond